The ASCO oral presentation on June 1, 2026, is a major near-term catalyst. Traders should monitor for overall survival (OS), progression-free survival (PFS), and safety data, which could drive sentiment ahead of the Phase 3 trial. A strong dataset may compress risk premium and re-rate the stock upward despite no immediate revenue impact.
Price Chart
Executive Summary
Immuneering Corporation announced that updated Phase 2a data from an expanded cohort of 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP will be presented at the 2026 ASCO Annual Meeting. The data readout, expected June 1, 2026, could serve as a key catalyst for the upcoming Phase 3 MAPKeeper 301 trial, which is set to begin dosing mid-2026.
Key Facts
- Updated Phase 2a data from 55 first-line pancreatic cancer patients will be presented orally at ASCO on June 1, 2026.
- The cohort includes 34 previously reported patients plus 21 newly added patients.
- Atebimetinib is an oral, once-daily MEK inhibitor designed to improve survival through durable tumor shrinkage, body mass preservation, and tolerability.
- First patient dosing in the pivotal Phase 3 MAPKeeper 301 trial is expected in mid-2026.
Financial Impact
Non-financial catalyst, but high clinical significance. Positive data could increase valuation ahead of Phase 3 initiation.
Risk Factors
- Clinical trial results may not meet expectations, leading to a sharp decline in stock price.
- Forward-looking statements highlight risks including regulatory uncertainty, funding needs, and lack of profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+1 | — | — |
Oct 2, 2026 24d ago | Press Release | $4.07 $4.04 | ▼ −0.74% | ▼ −1.41% | $3.73 (−8.35%) |
Sep 28, 2026 28d ago | Press Release | $4.16 $4.13 | ▼ −0.72% | ▼ −0.54% | $3.73 (−10.34%) |
Aug 26, 2026 8w ago | Press Release | $5.21 $4.99 | ▼ −4.22% | ▼ −4.00% | $3.73 (−28.41%) |
Aug 5, 2026 11w ago | 8-K | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Aug 5, 2026 11w ago | Press Release | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.12 $4.19 | ▲ +1.70% | ▲ +1.16% | $3.73 (−9.47%) |
Jun 1, 2026 21w ago | 8-K | $4.28 $4.55 | ▲ +6.31% | ▲ +7.00% | $3.73 (−12.85%) |
May 15, 2026 23w ago | Press Release | $5.16 $4.87 | ▼ −5.62% | ▼ −5.56% | $3.73 (−27.71%) |
Apr 21, 2026 26w ago | Press Release | $5.89 $6.13 | ▲ +4.07% | ▲ +4.47% | $3.73 (−36.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers